10-Q quarterly report · filed Nov 10, 2026

Revvity (RVTY) Q4 2026 10-Q Quarterly Report

Short answer

Revvity (RVTY) filed its Q4 2026 10-Q quarterly report on Nov 10, 2026 for the quarter ended Oct 4, 2026. Quarterly revenue was $729M (up 4.3% year over year) with net income of $62M.

Q4 2026 key financials · XBRL

Revenue
$729M
+4.3% YoY · −0.1% QoQ
Net income
$62M
+33.5% YoY · +20.2% QoQ
Operating margin
13.1%
EPS (diluted)
$0.56
+40.0% YoY · +21.7% QoQ

Source: XBRL data from the Revvity (RVTY) Q4 2026 10-Q on SEC EDGAR. USD.

Revvity Q4 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $728.9M, up 4% YoY from $698.9M
  • Life Sciences best performer: revenue $379.6M, up 11%; Diagnostics worst: $349.3M, down 2%
  • Gross margin 57.4% vs 53.6%; operating margin 13.1% vs 11.7% YoY
  • Cash $592.8M; operating cash flow $484.5M, up from $407.0M
  • $571.2M debt repayment; near-term outlook supported by sufficient internal cash for next 12 months

Risk Factors

  • Newly highlighted AI risk: flawed algorithms, biased datasets or evolving regulation could create liability, compliance costs and reputational damage
  • Most material regulatory update: U.S. funding and regulatory changes are making customers more cautious on instrumentation and consumables
  • Near-term market risk: tariff escalation and retaliation may materially hurt results despite manufacturing, supplier and pricing mitigation
  • Financial risk: substantial debt includes variable-rate and foreign-currency obligations, increasing interest and currency exposure
  • Compliance risk: FDA or foreign regulatory failures could trigger recalls, halted distribution, fines or criminal prosecution

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Revvity quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.